News

The promise of cellular therapies for MS

MS Research Australia and St Vincent’s Hospital have partnered to present to you an informative webinar discussing the latest research on Autologous Haematopoietic Stem Cell Transplantation (AHSCT) and MS.

SPEAKERS

Sophie Scott, National Medical Reporter, ABC
Sophie will be facilitating the webinar.

Associate Professor John Moore, Haematologist
John is one of Australia’s leading experts in AHSCT and has been involved in Australian AHSCT observational trials for the past ten years for people with MS who have failed multiple therapies.

Dr Jennifer Massey, Neurologist
Jennifer is the recipient of an MS Research Australia Postdoctoral Fellowship. Her research project is focused on examining the effects of stem cell transplant treatment on patients with MS. 

Ms Justine Marendziak, AHSCT recipient
Justine received AHSCT in 2016 at St Vincent’s to treat her MS after experiencing rapid deterioration and failing multiple other treatment options.

 

Click here for information on AHSCT and MS.

ofatumumab autoinjector pen

A reminder about PBS listing changes for REBIF and AVONEX

REBIF (interferon beta-1a) and AVONEX (interferon beta-1a) are currently used for the treatment of Australians living with relapsing forms of MS. Recently, there were some changes announced to their listing on the PBS.
autoinjector-pen

Changes announced to AVONEX listing on PBS

From 1 April 2023, AVONEX will no longer be available on the Pharmaceutical Benefits Scheme (PBS) for Australians living with MS.

What us to keep you in the loop? Subscribe today!

  • Enter your details

Read More
actrims-ectrims– impact on the MS community

Newsletter subscription

  • Enter your details

The promise of cellular therapies for MS